NCT01593150View on ClinicalTrials.gov

Early Versus Late DC-cardioversion of Persistent Atrial Fibrillation. Effect on Atrial Remodeling,Inflammatory and Neurohumoral Markers and Recurrence of Atrial Fibrillation

NACompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Atrial Fibrillation
Interventions
DRUG

Pradaxa

Pradaxa for 3 weeks prior to DC

PROCEDURE

TEE

Transesophageal echo to exclude LAA thrombus, followed by early DC.

OTHER

Compare TEE guided cardioversion to Dabigatran + DC cardioversion

compare the two groups, TEE followed by early DC cardioversion with Dabigatran for 3 weeks followed by DC cardioversion.

Trial Locations (1)

5700

OUH; Department of Medical Research, Svendborg Hospital, Svendborg

All Listed Sponsors
lead

Odense University Hospital

OTHER

NCT01593150 - Early Versus Late DC-cardioversion of Persistent Atrial Fibrillation. Effect on Atrial Remodeling,Inflammatory and Neurohumoral Markers and Recurrence of Atrial Fibrillation | Biotech Hunter | Biotech Hunter